17.38
Schlusskurs vom Vortag:
$17.00
Offen:
$17.18
24-Stunden-Volumen:
61,169
Relative Volume:
0.36
Marktkapitalisierung:
$269.21M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.87%
1M Leistung:
+2.54%
6M Leistung:
-17.67%
1J Leistung:
-7.41%
Neurogene Inc Stock (NGNE) Company Profile
Firmenname
Neurogene Inc
Sektor
Branche
Telefon
(877) 237-5020
Adresse
535 W 24TH STREET, NEW YORK
Compare NGNE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
NGNE
Neurogene Inc
|
17.38 | 263.33M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Craig Hallum | Buy |
| 2025-05-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-21 | Eingeleitet | William Blair | Outperform |
| 2024-01-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-05 | Eingeleitet | Stifel | Buy |
| 2024-01-04 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Neurogene Inc Aktie (NGNE) Neueste Nachrichten
Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit - Yahoo Finance
Aug Shorts: Whats the analyst consensus on Neurogene IncWeekly Investment Recap & Accurate Buy Signal Alerts - baoquankhu1.vn
Can Neurogene Inc. outperform under higher oil pricesJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - mfd.ru
Neurogene Inc. (NGNE) Stock Analysis: A 238% Potential Upside Awaits Investors - DirectorsTalk Interviews
Aug Catalysts: Is Neurogene Inc a potential multi bagger2025 Trading Volume Trends & AI Based Trade Execution Alerts - baoquankhu1.vn
Rare disease biotech Neurogene to field questions at 3 investor events - Stock Titan
Neurogene announces inducement grant under Nasdaq Listing Rule - marketscreener.com
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
One new Neurogene hire gets 2,820 stock options over 4 years - stocktitan.net
Aug Fed Impact: Is Walgreens Boots Alliance Inc forming a breakout patternJuly 2025 Drop Watch & Consistent Profit Trading Strategies - baoquankhu1.vn
Jobs Data: Does Neurogene Inc have a competitive edgeWeekly Gains Report & Expert-Curated Trade Recommendations - baoquankhu1.vn
Brokers Issue Forecasts for Neurogene FY2025 Earnings - MarketBeat
Neurogene (NASDAQ:NGNE) Now Covered by Analysts at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Neurogene (NGNE) with Outperform Recommendation - Nasdaq
Analysts Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $42.50 - Defense World
Neurogene Inc. (NASDAQ:NGNE) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Aug Macro: Is Neurogene Inc stock risky to hold nowQuarterly Portfolio Report & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Risk Analysis: Can Neurogene Inc outperform under higher oil pricesTrade Ideas & Reliable Momentum Entry Alerts - baoquankhu1.vn
NGNE: NGN-401 shows durable, multi-domain gains in Rett syndrome, advancing toward commercialization - TradingView
Neurogene (NASDAQ:NGNE) Given “Buy” Rating at HC Wainwright - Defense World
Fund Flows: Does EXTR stock have upside surprise potentialMarket Movers & Fast Momentum Entry Tips - baoquankhu1.vn
Market Fear: Whats the analyst consensus on Neurogene Inc2025 Market Trends & Daily Volume Surge Signals - baoquankhu1.vn
Short Covering: Whats the analyst consensus on Neurogene IncJuly 2025 WrapUp & Weekly Stock Breakout Alerts - baoquankhu1.vn
HC Wainwright & Co. Reiterates Buy Rating for NGNE with $70 Pric - GuruFocus
Neurogene doses multiple patients in Rett syndrome gene therapy trial By Investing.com - Investing.com Nigeria
Neurogene outlines 2026 milestones for NGN-401 Rett therapy - The Globe and Mail
Neurogene Inc. Reports Q3 2025 Financial Results - MSN
Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin By Investing.com - Investing.com South Africa
Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin - Investing.com Nigeria
Market Review: Whats the analyst consensus on Neurogene IncWeekly Trend Report & Weekly High Return Forecasts - baoquankhu1.vn
Neurogene doses multiple patients in Rett syndrome gene therapy trial - Investing.com
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome - marketscreener.com
Neurogene Inc Announces Key Milestones for NGN-401 Gene Therapy - TradingView — Track All Markets
Boston Herald - FinancialContent
Neurogene Announces Positive Interim Data for NGN-401 - MSN
User | custercountychief.comNeurogene Inc.Common Stock (Nasdaq:NGNE) Stock Quote - FinancialContent
Is Neurogene Inc. stock a good choice for value investors2025 Volatility Report & Safe Capital Allocation Plans - Улправда
Is Neurogene Inc. stock gaining market shareJuly 2025 Macro Moves & Consistent Return Investment Signals - Улправда
What insider purchases suggest about Neurogene Inc. (UU8) stockJuly 2025 Retail & Safe Entry Point Identification - Улправда
Neurogene Inc. (NGNE) Stock Analysis: Uncovering a 208% Potential Upside in Biotechnology - DirectorsTalk Interviews
Will Neurogene Inc. (UU8) stock attract long term capital inflows2025 Winners & Losers & Community Verified Trade Alerts - Улправда
How Neurogene Inc. (UU8) stock correlates with oil marketsAI-Driven Market Analysis & Free Realize Exceptional Returns - Улправда
Will Neurogene Inc. stock benefit from upcoming earnings reportsStock Price Forecasts & Minimal Investment Big Returns - ulpravda.ru
What analysts say about Neurogene Inc UU8 stockStock Liquidity Analysis & Free Stock Predictions and Analysis - Early Times
Shanti Educational Initiatives Limited (539921) Announces Strategic ShiftEarly Times Newspaper Jammu - Early Times
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference - New Castle News
Genetic medicines firm Neurogene opens its health conference talk online - Stock Titan
Neurogene Inc.Common Stock (NQ: NGNE - FinancialContent
Pullback Watch: Is Neurogene Inc stock a good choice for value investorsJuly 2025 Retail & AI Enhanced Trading Signals - moha.gov.vn
Breakout Move: How Applied Industrial Technologies Inc AT4 stock reacts to monetary easingTrend Reversal & Safe Swing Trade Setup Alerts - moha.gov.vn
Here's Why We're Not Too Worried About Neurogene's (NASDAQ:NGNE) Cash Burn Situation - Sahm
Finanzdaten der Neurogene Inc-Aktie (NGNE)
Es liegen keine Finanzdaten für Neurogene Inc (NGNE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):